SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('the Company') 
 
   Total voting rights 
 
   Oxford, UK, and Cambridge, MA, US 3 September 2018 -- Summit 
Therapeutics plc (AIM:SUMM, NASDAQ:SMMT), announces that in accordance 
with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's 
issued share capital as at the close of business on 31 August 2018 
consisted of 82,125,995 ordinary shares of 1 pence each ('Ordinary 
Shares'). There are no Ordinary Shares held in treasury. 
 
   Accordingly, the total number of voting rights in Summit Therapeutics 
plc at the date of this notice is 82,125,995. 
 
   The above figure of 82,125,995 may be used by shareholders as the 
denominator for the calculations by which they will determine if they 
are required to notify their interest in, or a change to their interest 
in, the Company under the FCA's Disclosure and Transparency Rules. 
 
   -END- 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programs focused on the genetic disease Duchenne 
muscular dystrophy and the infectious disease C. difficile infection. 
Further information is available at www.summitplc.com and Summit can be 
followed on Twitter (@summitplc). 
 
   For more information, please contact: 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)        Tel:    44 (0)1235 443 951 
Erik Ostrowski / Michelle Avery (US office)              +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                     Tel:   +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
 
 
 
 

(END) Dow Jones Newswires

September 03, 2018 06:00 ET (10:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024